Vitamin D is traditionally associated with bone metabolism. The immunological effects of vitamin D have increasingly come into focus.
SUMMARY Background
Vitamin D is traditionally associated with bone metabolism. The immunological effects of vitamin D have increasingly come into focus.
Aim
To review the evidence supporting a role of vitamin D in inflammatory bowel diseases.
Methods
A comprehensive search was performed on PubMed using the terms 'crohn's disease' 'ulcerative colitis' and 'vitamin D'.
Results

Vitamin D deficiency is common in patients with inflammatory bowel diseases (IBD) (16-95%) including those with recently diagnosed disease. Evidence supports immunological role of vitamin D in IBD.
In animal models, deficiency of vitamin D increases susceptibility to dextran sodium sulphate colitis, while 1,25(OH) 2 D 3 ameliorates such colitis. One prospective cohort study found low predicted vitamin D levels to be associated with an increased risk of Crohn's disease (CD). Limited data also suggest an association between low vitamin D levels and increased disease activity, particularly in CD. In a large cohort, vitamin D deficiency (<20 ng/mL) was associated with increased risk of surgery (OR 1.8, 95% CI 1.2-2.5) in CD and hospitalisations in both CD (OR 2.1, 95% CI 1.6-2.7) and UC (OR 2.3, 95% CI 1.7-3.1). A single randomised controlled trial demonstrated that vitamin D supplementation may be associated with reduced frequency of relapses in patients with CD compared with placebo (13% vs. 29%, P = 0.06).
Conclusion
There is growing epidemiological evidence to suggest a role for vitamin D deficiency in the development of IBD and also its influence on disease severity. The possible therapeutic role of vitamin D in patients with IBD merits continued investigation. 
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INTRODUCTION
Ulcerative colitis (UC) and Crohn's disease (CD) constitute chronic idiopathic inflammatory bowel diseases (IBD). The key underlying pathogenic mechanisms for both diseases is a dysregulated host immune response to commensal intestinal flora in genetically susceptible individuals. 1, 2 Known genetic variants incompletely explain the variance in disease incidence, suggesting a strong role for environmental factors, supported by epidemiological evidence. 3, 4 Vitamin D has long been recognised as a major regulator of calcium and phosphorus metabolism and key in maintaining bone health. [5] [6] [7] However, several recent studies have yielded new insights into the role of vitamin D in various other physiological processes. In particular, vitamin D appears to play important roles in immune regulation, particularly involving the innate immune system, cardiovascular and renal physiology, and development of cancer. 6 Importantly, an increasing body of literature supports an important role of vitamin D in the pathogenesis as well as potential therapy of IBD. [8] [9] [10] [11] [12] [13] The current review examines the evidence linking vitamin D to IBD, both through its effect on bone health and association with pathogenesis and natural history of these diseases.
METHODS
A comprehensive literature search on Pubmed was conducted using the following search terms: 'Crohn's disease' 'ulcerative colitis' and 'vitamin D' to identify relevant English language articles published between 1966 and 2013. In addition, bibliographies of the retrieved articles were searched to identify additional relevant articles.
RESULTS
Vitamin D synthesis
The main source of vitamin D is endogenous production in the skin where ultraviolet B energy in the sunlight converts 7-dehydrocholestrol to cholecalciferol (vitamin D3) ( Figure 1 ). 5, 14 Dietary contribution to vitamin D status includes foods such as egg yolk, beef liver, cod liver oil, fatty fish, fortified milk and milk products.
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Vitamin D from the endogenous production on exposure to sunlight as well as that absorbed from diet is Fats and fat-soluble vitamins are absorbed after emulsification by bile acids. The bile acid pool is maintained by an enterohepatic circulation occurring from the terminal ileum. Interruption of the enterohepatic circulation (e.g., by terminal ileal resection) could theoretically contribute to vitamin D deficiency. However, clinical data in support of this are conflicting. Terminal ileal resection was associated with vitamin D deficiency in some studies. 25, 26 In a study of 12 CD patients who underwent terminal ileal resection, absorption of vitamin D was reduced with the decline in absorption correlating with the length of the resected segment. However, other studies failed to identify an effect of ileal resection or active disease. 19 Malabsorption may theoretically contribute to low vitamin D in CD patients as vitamin D is absorbed in the proximal part of small intestine. The prevalence of vitamin D deficiency is higher in CD patients with upper gastrointestinal tract involvement. 27 However, when absorption of vitamin D was specifically tested, only 10% of patients with CD had decreased absorption of vitamin D compared to 50% of patients with pancreatic insufficiency. 28 There also appears to be a wide variation in absorption of vitamin D in patients with CD even in those with quiescent disease. 29 Protein-losing enteropathy occurs in some patients with IBD. As vitamin D and its metabolites circulate predominantly as bound forms to plasma vitamin D binding protein (DBP), the loss of DBP along with the bound vitamin D could be an additional plausible mechanism of vitamin D deficiency, particularly in those with severe disease. Finally, recent studies have suggested that genetic variants contribute both to development of vitamin D insufficiency and response to supplementation. In a genome-wide association study of nearly 30 000 individuals of European descent, variants at three loci near the genes involved in cholesterol synthesis, vitamin D hydroxylation and vitamin D transport were associated with vitamin D insufficiency. 30 The contribution of such genetic variants to vitamin D status in patients with IBD has not yet been studied. 37 In children, vitamin D deficiency results in poor mineralisation of the epiphyseal growth plates leading to bone deformities and stunted longitudinal growth, which are the typical features of rickets. In adults with vitamin D deficiency, there is defective mineralisation of the newly formed bone collagen matrix resulting in osteomalacia which manifests as bone pain, fractures and proximal muscle weakness. 5, 7, 16 There is a high prevalence of metabolic bone disease in patients with IBD. The prevalence of osteopenia ranges from 23% to 67% and osteoporosis from 7% to 35% among patients with CD or UC. [38] [39] [40] Active inflammatory disease is a strong risk factor for low bone mineral density (BMD) in patients with IBD, with BMD improving with increasing duration of remission. 41 This is supported by the known effect of TNF-a and other pro-inflammatory cytokines like IL-1, IL-6, IL-17 in activating osteoclasts. 42, 43 In addition, glucocorticoids use is an important risk factor for bone loss in patients with IBD. 39 However, the data linking vitamin D deficiency and impaired BMD in patients with IBD have been conflicting, with some studies supporting such an association and others finding no effect. Autophagy plays an important role in the pathogenesis of CD, and several lines of evidence support the hypothesis that the effect of vitamin D on IBD pathogenesis may be through this pathway. 1,25 (OH) 2 D helps in autophagy in macrophages by enhancing the co-localisation of pathogen harbouring phagosomes with autophagosomes in a cathelicidin-dependent manner. 49 Similar induction of autophagy by vitamin D has also been demonstrated in several models of cancer cell lines. Vitamin D3 has been hypothesised to regulate autophagy at several steps. 50 Increased calcium absorption mediated by the effect of vitamin D3 on the VDR can activate autophagy through various calcium-dependent kinases and phosphates, while vitamin D3 can itself downregulate the expression of mTOR, a negative regulator of autophagy. 50, 51 Vitamin D3 can also induce autophagy through increasing beclin-1 expression, a regulatory of autophagy, and activating the PI 3 K signalling pathway. [50] [51] [52] Vitamin D has been long used to treat mycobacterial infections 46, 53, 54 and vitamin D supplementation may reduce likelihood of tuberculin conversion. 55, 56 In a randomised controlled trial, vitamin D supplementation was associated with a reduced rate of development of a positive tuberculin reaction, suggesting a protective effect against tuberculosis infection in an endemic population. 56 Low serum vitamin D is also associated with reduced immunoreactivity to an anergy panel, and supplementation with vitamin D in anergic individuals with deficient levels restored delayed hypersensitivity response. 57 Vitamin D also plays a role in preventing over-activation of pro-inflammatory responses. 1,25(OH) 2 D within the monocytes dose-dependently inhibits lipopolysaccharide (LPS)-induced p38 phosphorylation and production of IL-6 and TNF-a in LPS-stimulated monocytes. 58 Antigen-presenting cells, including dendritic cells, express VDR. 59 The 71 Few studies have been able to examine the association between vitamin D status and incident IBD directly. One such study was using the Nurses' Health Study, a cohort of female registered nurses in the United States, followed prospectively using biennial questionnaires, and comprehensive assessment of diet and supplement intake and physical activity during the cohort follow-up timeline. 8 The vitamin D status of the participants was defined using a validated regression model incorporating race, diet, physical activity and region of residence. Over a 22-year follow-up, higher predicted plasma 25(OH)D leves was associated with a significant reduction in the risk of incident CD, but not UC. 8 develop an accelerated and severe form of IBD. However, when such mice were fed high-calcium diet and 1,25 (OH) 2 D, they developed only mild disease. 72 Both in TNBS-and DSS-induced colitis models, administration of 1,25(OH) 2 D led to an improvement in disease activity and addition of 1,25(OH) 2 D to a steroid regimen had a synergistic effect and this combination most effectively reduced the disease severity. 78 A novel vitamin D analogue with anti-proliferative effects and limited calcemic activity was also found to alleviate disease activity in mice with DSS-induced colitis. 78 There have been few human studies (Table 3) . Jorgensen et al. conducted a multicentre, randomised, double-blind, placebo-controlled trial in Denmark evaluating the efficacy of 1,25(OH) 2 D as a maintenance therapy in CD patients in remission. 12 One hundred and eight patients were randomised to receive either 1200 IU of 1,25(OH) 2 D with 1200 mg of calcium or 1200 mg of calcium alone daily over 1 year. Nearly one-third of the study population had vitamin D deficiency defined as serum 25(OH)D levels <50 nmol/L. Only 13% of patients in the vitamin D group relapsed during the 1-year study period compared to 29% in the placebo group (P = 0.06). 12 
